US › Healthcare

NRX Pharmaceuticals Inc (NRXP)

US · Healthcare · Biotechnology

$3.39+1.19%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.1M

Net profit

$-16.5M

EPS

$-0.18

EPS estimate

$-0.09

Net margin

-1,500.5%

EPS came in at -0.18 against a street estimate of -0.09 — a miss of 100.0%.

Key statistics

Market cap

$147.2M

Forward P/E

34.2

P/B

2.90

Book value

$-0.00

EPS (TTM)

$-0.51

52-week high

$5.05

52-week low

$1.62

50-day MA

$3.65

200-day MA

$2.87

Beta

2.19

Analyst view

Analysts rate NRX Pharmaceuticals Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $38.25.

Shareholding

Insiders

6.34%

Institutions

27.13%

Largest institutional holders

Fund	Stake
B Group, Inc	6.93%
Vanguard Capital Management, LLC	2.68%
AdvisorShares Investments, LLC	1.52%
Commonwealth Equity Services, LLC	1.05%
Geode Capital Management, LLC	0.72%
Vanguard Fiduciary Trust Co	0.39%
Bleakley Financial Group LLC	0.27%
BlackRock Inc	0.23%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NRX Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.